Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2012. The report details a specific share repurchase transaction executed on February 14, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share capital movements.
- Shares Purchased: 205,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,444.0 pence per share; lowest price paid was 1,424.0 pence per share.
- Treasury Holdings (Settled): 502,157,927 shares (9.04% of total issued share capital).
- Treasury Holdings (Including Unsettled): 503,067,927 shares (9.96% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,051,174,462 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 205,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 9.96% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. It is a compliance disclosure regarding share buybacks under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury against the latest quarterly or annual reports to confirm the 9.04% to 9.96% range.
- Confirm the total issued share capital of 5,051,174,462 shares (excluding Treasury) for accurate voting rights calculations.
- Check subsequent filings to determine if the 205,000 shares purchased on February 14, 2012, were fully settled and cancelled or retained in Treasury.